TOKYO, Mar 23, 2023 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today the company will present the latest findings on lecanemab (generic name, U.S. brand name: LEQEMBI), Eisai’s anti-amyloid beta (Aβ) protofibril* antibody for the treatment of Alzheimer& […]